2023-06-27 18:44:37
Updated Tuesday, June 27, 2023 – 18:44
The areas of rare childhood diseases, transplants, traumatology, cancer immunotherapy and, for the first time, mental health will benefit from the grants from the Mutua Madrilea Foundation
One of the operating rooms of the new surgical block of the Gregorio Maran Hospital. ANTONIO HEREDIA
The Mutua Madrilea Foundation has delivered today his twentieth call for Health Research Grantsendowed with 2.3 million euros, to 26 clinical studies that will be carried out in hospitals throughout Spain. Research will be carried out in the area of transplants, rare childhood diseases, traumatology, cancer immunotherapy and child and adolescent mental health.
The award ceremony was chaired by the president of Grupo Mutua and its foundation, Ignacio Garralda, and was attended by the president of the Scientific Committee of the Mutua Madrilea Foundation, Dr. Rafael Matesanz, and the scientific researcher of the Severo Ochoa Molecular Biology Center (CSIC-UAM) and coordinator of the Global Health Interdisciplinary Thematic Platform (CSIC), Dr. Margarita del Val.
In its first 20 years of life, which the Fundación Mutua Madrilea celebrates this year, has already allocated 68 million euros to this annual call of aid with which it contributes to quality medical research carried out in Spain and which has served to launch more than 1,400 projects. In this twentieth edition, the foundation will support the work of research teams from 22 hospitals in 9 different autonomous communities.
The research projects have been selected by the foundation’s scientific committee and will be carried out in the areas of transplants, focused on immune tolerance and organ preservation (4 studies), traumatology and its sequelae (5 studies), rare diseases that manifest in childhood (4 studies), Immunotherapy focused oncologist (5 studies) and mental health, focused on child and adolescent disorders (4 studies). Additionally, another 4 studies led by specialists from the medical staff of adeslasa leading health insurance insurance company belonging to Grupo Mutua.
Collaboration between groups from all over Spain
In this selection of 26 studies there are two that are collaborative, in which teams from at least four different autonomous communities participate. One of them, in the field of cancer immunotherapy, use liquid biopsy -a test that analyzes genetic lesions in cells from the tumor that circulate in the patient’s blood- to identify genetic, epigenetic and gene expression alterations in tumor samples of patients with small cell (microcytic) lung cancer. This type of lung cancer it accounts for around 25% of the total and is the one with the lowest life expectancy and the worst response to treatment. In addition, it is usually detected when it has already originated metastasis.
Family photo of the beneficiaries in which in the center, from left. to right appearing: Dr. Margarita del Val, scientific researcher at the Severo Ochoa Molecular Biology Center (CSIC-UAM); Ignacio Garralda, president of Grupo Mutua and its foundation; and Dr. Rafael Matesanz, president of the Scientific Committee of the Mutua Madrilea.FM Foundation.
The aim of this collaborative study is improve early detection and find new treatments for this lung tumor. “The culture of these cells will also allow the testing of new drugs directed against the detected alterations and to test ways to give sensitivity to immunotherapy. This precision oncology is expected to contribute to improving the clinical management of patients with this type of tumor”, explains doctor Manel Esteller, coordinator of the study through the Germans Trias i Pujol Health Research Institute (IIS) of Barcelona. Teams from the Health Research Institutes of Navarra, Santiago de Compostela and Virgen de las Nieves of Granada are participating with his group.
The other collaborative study will be developed in the area of traumatology and assess the efficacy of a drug in patients with head trauma, concussions and pericontusional edema in a prospective, randomized, double-blind study. This study continues a previous investigation, financed by the Mutua Madrilea Foundation and led by Dr. Juan Pérez Bárcena, from the Son Espases Hospital in Majorca, which confirmed that dexamethasone, a powerful anti-inflammatory, is a valid treatment for head trauma, a global public health problem due to its enormous prevalence, high mortality and lack of treatment, and which can be caused by a bad fall, a blow or a traffic accident. In addition to your hospital, hospitals will participate in the study. October 12 in Madrid; General of Burgos; Marqus de Valdecilla in Santander, University of Salamanca, University of Toledo, Ro Hortega en Valladolid; General of Castelln; Arnau de Vilanova in Lleida y Santa Creu and San Pauin Barcelona.
Mental health, new call
The novelty of this year’s call is the introduction of the area of mental health. In this field, four works will be financed focused on delving into different pathologies of children and adolescents, among them, one to prove therapy for anorexia nervosa, an orphan disorder of treatmentsfrom the Health Research Institute (IIS) of La Fe de Valencia (Dr. Luis Miguel Rojo); and another to study different therapies for the fetal alcohol spectrum disorder (TEAF), in the Hospital Clinic-Idibaps of Barcelona (Doctor Scar Garcia-Algar).
Other specialties
Four other works will address different aspects of immunotherapy for different types of tumor, a couple of them focused on the development of a CAR-T therapy. Thus, at the IIS Reina Sofia in Córdoba, Dr. Javier Caballero will develop and carry out the analysis of the safety, viability and effectiveness of tandem CAR-T cells. targeting glioblastoma multiformea very aggressive type of brain tumor.
In transplantation, two of the studies will focus on the kidney transplantsuch as the one that Dr. Alberto Lzaro carried out in the Gregorio Marán Hospital in Madrid for pharmacological modulation of reperfusion injury in renal grafts using cilastatina drug for which this group has found in previous studies, also financed by the Mutual Foundation, significant kidney protection properties in various circumstances.
In the area of rare diseases that manifest in childhood, with which the Mutual Foundation has been committed for more than a decade, another four studies will be financed to continue advancing in the knowledge and treatment of different pathologies.
Health cooperation scholarships
On the spot, they have delivered four international cooperation scholarships to health professionals who provide care work as volunteers in different countries of Africa.
According to the criteria of The Trust Project
Know more
#million #euros #medical #research #projects #Spanish #hospitals